NASDAQ:TNXP Tonix Pharmaceuticals Q3 2025 Earnings Report $19.70 -0.14 (-0.71%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$19.34 -0.36 (-1.80%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Tonix Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$3.59Beat/MissN/AOne Year Ago EPSN/ATonix Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$2.30 millionBeat/MissN/AYoY Revenue GrowthN/ATonix Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Tonix Pharmaceuticals Earnings HeadlinesTonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) ConvergenceOctober 21 at 7:46 AM | finance.yahoo.comTonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) ConvergenceOctober 21 at 7:00 AM | globenewswire.comThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they understand the why, when, and how of crypto. Join our free 2‑day virtual summit and learn directly from the world’s top hedge fund managers who’ve built real portfolios and real wealth. You’ll walk away with actionable insights grounded in strategy—not hype. No FOMO. No fluff. Just clear steps to move from intrigued to informed about crypto. | Crypto 101 Media (Ad)Tonix Pharmaceuticals presents data on TNX-801 Mpox vaccineOctober 17, 2025 | msn.comTonix Pharmaceuticals Presents Promising Preclinical Data for TNX-801 Vaccine Against Mpox and Smallpox at World Vaccine Congress–Europe 2025October 17, 2025 | quiverquant.comQTonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025October 17, 2025 | globenewswire.comSee More Tonix Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email. Email Address About Tonix PharmaceuticalsTonix Pharmaceuticals (NASDAQ:TNXP) is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents. Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD. The company is conducting late-stage clinical trials to assess safety and efficacy in people who experience chronic pain and disrupted sleep due to these conditions. In addition to its CNS portfolio, Tonix is advancing live-virus vaccine candidates against orthopoxviruses, including those that could be used for smallpox or monkeypox, and is exploring development of vaccines against other biothreat agents. Headquartered in New York, Tonix Pharmaceuticals leverages in-house research and collaborations with academic institutions and government agencies to advance its pipeline. The company was co-founded and is led by Seth H. Lederman, M.D., who serves as President and Chief Executive Officer. Under Dr. Lederman’s direction, Tonix continues to progress multiple programs through clinical development while maintaining a focus on unmet medical needs in both therapeutic and vaccine arenas.View Tonix Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings Intel (10/23/2025)Honeywell International (10/23/2025)T-Mobile US (10/23/2025)Lloyds Banking Group (10/23/2025)Vale (10/23/2025)Freeport-McMoRan (10/23/2025)Newmont (10/23/2025)Blackstone (10/23/2025)Digital Realty Trust (10/23/2025)Union Pacific (10/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
